Megalax(300 mg+1.25 ml)/5 ml

Megalax is indicated for the short-term relief of occasional constipation. It combines an osmotic (saline) laxative effect with a lubricant/stool-softening effect, making it useful in the following situations:

• Occasional/simple constipation: First-line, established use for short-term relief of infrequent or difficult bowel movements.
• Constipation where straining should be avoided: Commonly used as an adjunct when patients need to avoid straining at stool, such as after anorectal surgery, in the presence of painful hemorrhoids, or with an anal fissure, since the lubricant component eases passage of stool without excessive straining.
• Bowel preparation/adjunct use: Occasionally used as an adjunct to bowel evacuation regimens under medical supervision; this is a supportive rather than a primary indication.

Megalax is not intended for long-term or habitual use in chronic constipation without medical evaluation of the underlying cause.

Magnesium Hydroxide + Liquid Paraffin is available as an oral liquid (emulsion/suspension). Each dose (commonly per 5 mL or 15 mL, depending on brand) contains a combination of:

• Magnesium Hydroxide (BP/USP) - an osmotic/saline laxative and antacid.
• Liquid Paraffin (Light and/or Heavy Liquid Paraffin, BP/USP) - a mineral-oil-based lubricant laxative.

Exact strengths differ between manufacturers and brands; always check the product label or package insert for the precise quantity of each active ingredient in the specific brand dispensed.

Megalax is a fixed-dose combination oral laxative that pairs an osmotic laxative (magnesium hydroxide) with a lubricant laxative (liquid paraffin, also known as mineral oil). Magnesium hydroxide draws water into the intestinal lumen and softens stool while stimulating bowel motility, and liquid paraffin coats and lubricates the stool and intestinal wall, easing the passage of stool with less straining.

Megalax is typically supplied as an oral emulsion/suspension and is used for the short-term management of occasional constipation, including situations where straining during defecation should be minimized.

Megalax belongs to the therapeutic class of laxatives, specifically a combination of an osmotic (saline) laxative and a lubricant laxative, used in the management of constipation.

Pharmacodynamics

Magnesium Hydroxide + Liquid Paraffin works through two complementary mechanisms. Magnesium hydroxide is poorly absorbed from the gastrointestinal tract; the unabsorbed magnesium ions create an osmotic gradient that draws water into the intestinal lumen, increasing stool volume and softness and stimulating peristalsis, typically producing a bowel movement within 30 minutes to 6 hours. Liquid paraffin, an inert mineral oil, is not digested or significantly absorbed; it coats the fecal mass and the intestinal mucosa, reducing water absorption from the stool and lubricating its passage, generally acting within 6 to 8 hours.

Pharmacokinetics

Magnesium hydroxide undergoes minimal systemic absorption (roughly 5-10% of an oral dose) with the absorbed fraction excreted renally; absorption and excretion can be reduced in renal impairment, raising the risk of accumulation. Liquid paraffin is largely non-absorbed and is excreted mostly unchanged in the feces, though a small amount may be absorbed and deposited in intestinal tissue with chronic use.

• Shake the bottle well before each use, as Megalax is an emulsion/suspension.
• Take Megalax by mouth, measured with an appropriate measuring cup or spoon.
• Do not take Megalax immediately before lying down or at bedtime, and do not take it while lying flat, because of the risk of aspiration and lipoid pneumonia associated with the liquid paraffin component (see Precautions and Warnings).
• Separate administration of Megalax from other oral medicines (e.g., tetracyclines, fluoroquinolones) by at least 2 hours, since it can reduce their absorption (see Interaction).
• Use for short-term relief of occasional constipation only; do not use for more than 1 week without medical advice.

• Fat-soluble vitamins (A, D, E, K): Regular or prolonged use of the liquid paraffin component of Megalax can reduce absorption of fat-soluble vitamins, potentially leading to deficiency with chronic use.
• Tetracyclines and fluoroquinolone antibiotics: The magnesium hydroxide component of Megalax can chelate and reduce absorption of these antibiotics, lowering their effectiveness; doses should be separated by at least 2 hours.
• Docusate sodium (stool softeners): Concurrent use with docusate sodium is generally avoided, as docusate may increase systemic absorption of liquid paraffin.
• Oral anticoagulants (e.g., warfarin): Chronic use of Megalax may reduce vitamin K absorption and enhance the effect of oral anticoagulants; monitoring is advised with prolonged concurrent use.
• Other oral drugs generally: As with other magnesium-containing antacid/laxative products, Megalax may reduce or delay absorption of other concurrently administered oral medicines; separating dosing by 2 or more hours is generally advisable.

Side effects of Megalax are generally dose-related and include:

• Diarrhea and abdominal cramping, especially with higher doses.
• Nausea.
• Anal seepage/leakage of oil and soiling of undergarments, a recognized nuisance effect of the liquid paraffin component, particularly with excessive or prolonged dosing.
• Pruritus ani (anal itching) related to oil leakage.
• Hypermagnesemia with excessive or prolonged use, or in patients with renal impairment (see Contraindications); symptoms can include lethargy, weakness, nausea, and in severe cases, low blood pressure or cardiac effects.
• Lipoid pneumonia (rare, seen mainly with aspiration of the liquid paraffin component - see Precautions and Warnings).

Pregnancy: Megalax should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk; consult a physician before use. Occasional, short-term use is generally considered acceptable, but regular or prolonged use of the liquid paraffin component is generally discouraged during pregnancy, because reduced absorption of fat-soluble vitamins (particularly vitamin K) could theoretically affect maternal and neonatal vitamin K-dependent clotting factors, which is of particular concern around the time of delivery.

Lactation: Data on excretion into breast milk are limited. Magnesium hydroxide is poorly absorbed systemically and occasional use is generally considered compatible with breastfeeding; liquid paraffin is not expected to be absorbed to a clinically significant degree. Nonetheless, Megalax should be used during breastfeeding only if clearly needed, and a physician should be consulted.

• Aspiration/lipoid pneumonia risk: Because Megalax contains liquid paraffin, it should not be taken immediately before bedtime or while lying down, as aspiration of liquid paraffin into the lungs can cause lipoid pneumonia. This risk is particularly significant in elderly, debilitated, or bedridden patients and in those with swallowing difficulties (dysphagia) or a reduced gag reflex; use in such patients should generally be avoided (see Contraindications).
• Duration of use: Megalax is intended for short-term use only and should not be used continuously for more than 1 week without medical advice; persistent constipation should be medically evaluated.
• Renal impairment: Use with caution and avoid regular/prolonged use in patients with reduced kidney function, due to the risk of magnesium accumulation.
• Chronic/regular use: Prolonged regular use of Megalax may reduce absorption of fat-soluble vitamins (A, D, E, K) - see Interaction.
• Elderly patients: Use with caution given the increased risk of aspiration and renal impairment in this population.

Overdose of Megalax may cause severe diarrhea, abdominal cramping, and dehydration with associated electrolyte disturbances. In patients with renal impairment, or with very large or repeated overdoses, hypermagnesemia can occur, with symptoms such as nausea, vomiting, facial flushing, lethargy, muscle weakness, low blood pressure, and, in severe cases, cardiac arrhythmia or respiratory depression. Aspiration of a large amount of liquid paraffin can increase the risk of lipoid pneumonia. In the event of a suspected overdose of Megalax, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment beyond general supportive measures advised by a healthcare professional.

Store at room temperature (below 30°C), away from light and moisture. Shake well before use. Keep out of reach of children.

• Renal impairment: Use Megalax with caution; avoid regular or prolonged use due to the risk of magnesium accumulation and hypermagnesemia (see Contraindications and Precautions and Warnings).
• Hepatic impairment: No well-established dose adjustment is available; use with general caution as with other laxatives.
• Elderly: Increased risk of aspiration/lipoid pneumonia and of renal impairment; use the lowest effective dose and avoid administration at bedtime or while reclining (see Precautions and Warnings).
• Children: Not recommended in children under 6 years without medical advice; use in older children should be supervised by a physician (see Pediatric Uses).
• Pregnancy and lactation: See Pregnancy and Lactation section for detailed guidance.

Megalax is intended for short-term, occasional use only and should not be taken continuously for more than 1 week without medical advice. If constipation persists beyond this period, or recurs frequently, a physician should be consulted to evaluate the underlying cause rather than continuing self-treatment.

Combination laxative: osmotic (saline) laxative + lubricant laxative; also referenced within antacid-laxative combination products.

Magnesium Hydroxide + Liquid Paraffin acts via two distinct, complementary laxative mechanisms. The magnesium hydroxide component acts osmotically: poorly absorbed magnesium ions retain water within the bowel lumen, increasing intraluminal volume and pressure, which mechanically stimulates peristalsis and softens stool. The liquid paraffin component acts as a lubricant: being an indigestible mineral oil, it forms a film over the fecal mass and colonic mucosa that reduces colonic water reabsorption from the stool and decreases friction, allowing easier, less strained evacuation.

The safety and efficacy of Megalax in young children have not been well established, and its use in children under 6 years of age is not recommended without medical advice, largely because of the aspiration/lipoid pneumonia risk associated with the liquid paraffin component in a population more prone to swallowing difficulty and reflux. In children aged 6-12 years, Megalax may be used only under the guidance and supervision of a physician, at a reduced dose compared with adults. Megalax should never be given to an infant or a child who has difficulty swallowing.